217099-09-7

Upstream product

• 183550-78-9 5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxylic acid 
• 508210-17-1 8-Oxo-5-p-tolyl-8H-pyrano[3,4-b]pyridine-6-carbonyl chloride 
• 85068-29-7 3,5-bis-trifluoromethylbenzylamine 
• 183550-80-3 N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-methylphenyl)-8-oxo-8H-pyrano[3,4-b]pyridine-6-carboxamide 

Downstream Products

• 183550-82-5 N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-7-(4-hydroxybutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide 

Relevant academic research and scientific papers

Enantioselective synthesis of an axially chiral 1,7-naphthyridine-6-carboxamide derivative having potent antagonist activity at the NK1 receptor

A new and highly potent NK1 antagonist, (aR,9R)-3 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4- methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione], was atropdiastereoselectively synthesized in